A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 4, 2008, Pages 221-227

  Balkissoon, Ron ^a   Make, Barry ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Albuterol; Atrouent; Combination therapy; COPD; Fluticasone; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOSE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; POTASSIUM; SALBUTAMOL SULFATE; SHORT ACTING DRUG;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; DYSURIA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HOARSENESS; HUMAN; LUNG FUNCTION; MALE; NEUROLOGIC DISEASE; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IPRATROPIUM; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROBABILITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 48749098264     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550802237408     Document Type: Article

References (19)

1. Cazzola M, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89(5):357-362.
2. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4):1283-1289.
3. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001; 18(6):441-472.
4. Donohue JF, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1):47-55.
5. Ferguson GT, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003. 123(6):1817-1824.
6. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61(2):122-128.
7. Dorinsky PM, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115(4):966-971.
8. Petty TL. The combination of ipratropium and albuterol is more effective than either agent alone. Chest 1995; 107(5 Suppl):183S-186S.
9. van Noord JA, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55(4):289-294.
10. Hanania NA, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834-843.
11. Calverley PM, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775-789.
12. Dorinsky PM, et al. Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy.
13. Casaburi R, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2):217-224.
14. Vincken W, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209-216.
15. O'Donnell DE, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23(6):832-840.
16. Make B, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005; 27(5):531-542.
17. Calverley PM, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58(10):855-860.
18. Mahler DA, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084-1091.
19. Calverley P, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361(9356):449-456.